

Supplemental material

Table S1. Non-cardiac DB-drugs included in this study were defined as drugs listed on the www.brugadadrugs.org website
amitriptyline (N06AA09), clomipramine (N06AA04), lithium (N05AN01), nortryptiline (N06AA10), oxcarbazepine (N03AF02), carbamazepine (N03AF01), dosulepin (N06AA16), doxepin (N06AA12), fluoxetine (N06AB03), fluvoxamine (N06AB08), imipramine (N06AA02), lamotrigine (N03AX09), maprotiline (N06AA21), paroxetine (N06AB05), phenytoin (N03AB02), tramadol (N02AJ13, N02AX52, N02AX02), indapamide (C03BA11), metoclopramide (A03FA01), fexofenadine (R06AX26), bupropion (N06AX12, N07BA02)
Not included in this study since these drugs were not registered in The Netherlands or there were no users in our dataset: desipramine, trifluorperazine, bupivacaine, procaine, propofol, thioridazine, ketamine, diphenhydramine

Table S2. Risk for out-of-hospital cardiac arrest upon use of non-cardiac depolarization blocking drugs: stratification according to cardiovascular drugs use				
	OHCA-cases	Non-OHCA controls	Crude OR*	Adjusted OR†
Cardiovascular drugs use	3516	8551		
No use of any non-cardiac DB-drugs	3193 (90.8)	7961 (93.1)	1.0 (reference)	1.0 (reference)
Use of non-cardiac DB-drugs	323 (9.2)	590 (6.9)	1.3 (1.2-1.6)	1.3 (1.2-1.5)
No cardiovascular drugs use	1957	13315		
No use of any non-cardiac DB-drugs	1853 (94.7)	13070 (98.2)	1.0 (reference)	1.0 (reference)
Use of non-cardiac DB-drugs	104 (5.3)	245 (1.8)	2.9 (2.3-3.7)	2.8 (2.2-3.6)
OR, odds ratio. Numbers are number (%) unless indicated otherwise. P-value interaction stratification according cardiovascular disease <0.001. *Adjusted for age and sex. †Adjusted for age, sex and use of antidiabetics				

Table S3. Risk for out-of-hospital cardiac arrest upon use of non-cardiac depolarization blocking drugs with or without QT-prolonging potential				
	OHCA-cases	Non-OHCA controls	Crude OR	Adjusted OR
	5473	21866		
No use of any non-cardiac DB-drugs	5046 (92.2)	21031 (96.2)	1.0 (reference)	1.0 (reference)
Use of non-cardiac DB-drugs with QT-prolonging potential	362 (6.6)	723 (3.3)	2.1 (1.8-2.4)	1.6 (1.4-1.8)
Use of non-cardiac DB-drugs without QT-prolonging potential	58 (1.1)	96 (0.4)	2.5 (1.8-3.5)	2.1 (1.5-2.9)
OR, odds ratio. Numbers are number (%) unless indicated otherwise. Odds ratio adjusted for use of cardiovascular drugs, antidiabetics and Vaughan-Williams class I or III antiarrhythmic drugs. Combined use of non-cardiac DB-drugs included and not included in www.CredibleMeds.org : cases (%)/controls (%) = 7 (0.1)/16 (0.1)				
Use of non-cardiac DB-drugs listed in www.CredibleMeds.org : amitriptyline, clomipramine, desipramine, lithium, nortryptiline, bupivacaine, procaine, propofol, doxepin, fluoxetine, fluvoxamine, imipramine, maprotiline, paroxetine, thioridazine, tramadol, diphenhydramine, indapamide, metoclopramide				
Use of non-cardiac DB-drugs not listed in www.CredibleMeds.org : oxcarbazepine, trifluorperazine, bupropion, carbamazepine, dosulepine, lamotrigine, phenytoin, ketamine, fexofenadine				

Table S4. Number of drugs being simultaneously dispensed		
	Cases (5473)	Controls (21866)
Number of drugs		
0	1902 (34.8)	13154 (60.2)
1	615 (11.2)	1931 (8.8)
2	609 (11.1)	1902 (8.7)
3	631 (11.5)	1790 (8.2)
≥4	1716 (31.4)	3089 (14.1)